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1 Background
A 66-year-old white female s/p mitral and tricuspid valve re-
placement was seen in cardiac consultation and diagnosed with
atrial fibrillation and high-degree atrioventricular (AV) block
with symptomatic bradycardia, thus pacemaker placement
was recommended. For this particular patient, a standard,
single-lead implantable pacemaker, while not contraindicated,
was not a preferable solution due to the patient’s newly im-
planted bioprosthetic tricuspid valve and the potential compli-
cations transvalvular lead placement may bring [1]. No FDA-
approved leadless pacemaker is available in the USA at this
time; however, initial safety and feasibility trials have shown
comparable results to traditional transvenous leads [2].
2 Procedure
TheMinneapolis Heart Institute Foundation (MHIF) at Abbott
Northwestern Hospital is part of Medtronic’s Micra Trans-
catheter Pacing FDA IDE trial. The Micra system departs
from the traditional design. The pacing capsule is quite small
(2.0 g, 0.8 cc) compared with a traditional implantable gener-
ator with the added benefit of being leadless.
The contact point for sensing and energy delivery is posi-
tioned on one end of the housing and held against the endo-
cardium via flexible nitinol tines. The implant procedure is
also unique in that it is deployed via catheter through the
femoral vein rather than the standard pocket formation and
access through the axillary veins.
At the start of the procedure, the right femoral vein was
entered using the micropuncture technique. Sequential dilata-
tion was performed using an 8 French, 16 French, and then
ultimately the large bore 23 French Micra introducer.
Once the large bore sheath had been placed and advanced
over a stiff guidewire to the right atrium, the Micra pacemaker
was advanced through this sheath, and using catheter manip-
ulation, directed through the bioprosthetic tricuspid valve to-
ward the apex of the right ventricle. The initial attachment
point in the apex while anatomically stable was ultimately
unsuccessful due to insufficient electrical measurements.
The pacing capsule was retrieved and redeployed in a second
spot closely adjacent, which demonstrated excellent sensing
and pacing characteristics. Stability was confirmed using the
pull and hold test to assure at least two tines were engaged.
After confirming stability, and assessing electrical parameters
again, the tether was cut and slowly removed, the delivery cath-
eter and sheath were removed, and the insertion site was closed
with a figure 8 stitch. This was the first implant of its kind at this
institution. The implant procedure lasted approximately 45 min
from initial puncture through closure. The elapsed time was
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31 min from the point at which the TPS was inserted into the
sheath until the delivery tool was removed.
Micra Pacemaker Deployed – Tether (not visible under fluoroscopy) Remains Connected During “Tug Test”
After confirming stability, and assessing electrical 
parameters again, the tether was cut and slowly 
removed, the delivery catheter and sheath were 
removed and the insertion site was closed with a figure 
8 stitch. This was the first implant of its kind at this 
institution. The implant procedure lasted approximately 
45 minute from initial puncture through closure. The 
elapsed time was 31 minutes from the point at which 
the TPS was inserted into the sheath until the delivery 
tool was removed.
3 Performance
Six months post-implant, the patient has had no complications
from the procedure or any other cardiovascular-related adverse
events. Device data comparing the day of discharge to the 6-
month follow-up show acceptable performance and battery
longevity:
Discharge measurements 6-Month measurements
Vsense 11.5 mV Vsense >20.0 mV
Vcapture 0.38 V @
0.24 ms
Capture 0.38 V @
0.24 ms
Impedance 650Ω Impedance 900Ω






Longevity est. >13 Years Longevity est. >13 Years
Echocardiographic follow-up indicates no significant
changes in tricuspid valve performance:
TTE—05/2014 TTE—03/2015
TR TRACE TRACE
TV mean gradient 4.1 mmHg 3.0 mmHg
TRVmax 2.5 m/s 2.3 m/s
4 Discussion
For our patient, a pacing lead permanently placed through the
newly implanted bioprosthetic tricuspid valve is less than ide-
al as valvular insufficiency could be a concern. Thus, the
transcatheter system seemed to have a significant advantage.
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